Abcellera Biologics Inc (ABCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has a cash flow conversion efficiency ratio of -0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.86 Million) by net assets ($896.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Abcellera Biologics Inc for the company's overall valuation and market capitalisation.
Abcellera Biologics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Abcellera Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abcellera Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abcellera Biologics Inc ranked by their cash flow conversion efficiency. Explore ABCL operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gulfport Energy Operating Corp
NYSE:GPOR
|
0.162x |
|
Dongfeng Motor Group Company Limited
F:D4D
|
-0.026x |
|
Black Stone Minerals LP
NYSE:BSM
|
0.083x |
|
Bank of Hawaii Corporation
NYSE:BOH
|
0.021x |
|
Shanghai Daimay Auto Interior
SHG:603730
|
0.049x |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
0.121x |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
0.143x |
|
Tian Di Science & Technology Co Ltd
SHG:600582
|
0.005x |
Annual Cash Flow Conversion Efficiency for Abcellera Biologics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Abcellera Biologics Inc from 2018 to 2025. View Abcellera Biologics Inc (ABCL) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $966.90 Million | $-131.29 Million | -0.136x | -32.10% |
| 2024-12-31 | $1.06 Billion | $-108.56 Million | -0.103x | -169.95% |
| 2023-12-31 | $1.15 Billion | $-43.88 Million | -0.038x | -116.93% |
| 2022-12-31 | $1.23 Billion | $277.36 Million | 0.225x | -5.68% |
| 2021-12-31 | $1.03 Billion | $244.58 Million | 0.238x | +772.78% |
| 2020-12-31 | $830.51 Million | $22.69 Million | 0.027x | -89.60% |
| 2019-12-31 | $10.25 Million | $2.69 Million | 0.263x | -14.43% |
| 2018-12-31 | $11.61 Million | $3.56 Million | 0.307x | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more